[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bacteremia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bacteremia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,80,103,126,154,183,203,230,256,286,316,342,395,417,439,465],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100498466","phase-4-improving-therapeutic-drug-monitoring-and-dosing-for-vancomycin-in-young-infants-with-infections-vancapp-part-2-100498466",false,"NCT05770622","Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)","The VANcomycin Cohort Study - Assessing Precise Dosing and Prompt Drug Monitoring to Improve Attainment of Target Concentrations (Part 2)","VANCAPP","Inclusion Criteria:\n\n* Infants aged 0 - 90 days old\n* Suspected infection requiring treatment with vancomycin for 48 hours or more (as determined by the clinical team)\n\nExclusion Criteria:\n\n* Infants with a corrected gestational age of less than 25 weeks\n* Infants weighing less than 500g.\n* Known allergy to any glycopeptide antibiotic\n* Vancomycin administered within the previous 72 hours\n* Infants receiving any form of extracorporeal life support\n* Renal impairment","ALL","0 Days","90 Days",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","A challenge to intermittent vancomycin dosing in young infants is the avoidable delay caused by the need to wait until steady state (i.e. when the drug concentrations are in equilibrium) to measure a vancomycin concentration, as this generally occurs 24 to 48 hours after starting treatment. If the target concentration is not achieved, the dose needs to be adjusted, resulting in further delays in an infant achieving the concentration required to treat their infection. The purpose of this study is to assess the use of early therapeutic drug monitoring (first-dose trough) and, if needed, early dose adjustment, in achieving target vancomycin concentrations at steady state. A dose adjustment calculator (available through a web application) will be used to determine the need for dose adjustment (based on predicted steady state concentration) and recommend an adjusted dose if required.",[28,29,30],"Sepsis","Infections","Bacteremia","RECRUITING","2026-04-15",{"date":34,"type":35},"2026-04-20","ACTUAL",{"date":37,"type":35},"2024-11-10",{"date":39,"type":22},"2027-04",{"name":41,"class":42},"Murdoch Childrens Research Institute","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100603302","febrile-infants-swedish-study-100603302","NCT07134751","Febrile Infants Swedish Study","FISS","Inclusion Criteria:\n\n* Temperature ≥38.0 C (measured either at home or at the pediatric emergency department)\n* Age ≤60 days","60 Days",{"count":53,"type":22},2000,"OBSERVATIONAL","Approximately one million febrile infants aged ≤60 days present annually to pediatric emergency departments (PEDs) in Europe and the United States. Although fewer than 5% are diagnosed with meningitis or bacteremia (invasive bacterial infections - IBIs), and 10-15% with urinary tract infections (UTIs), current guidelines recommend extensive diagnostic evaluations, hospitalization, and empirical treatment with broad-spectrum parenteral antibiotics. This approach may contribute to medical overuse, with implications for patient care, healthcare resource utilization, and environmental sustainability.\n\nThe Febrile Infants Swedish Study (FISS) is a prospective observational study conducted across 11 PEDs in Sweden. All febrile infants aged ≤60 days presenting to participating sites will be eligible. A new clinical guideline for the management of infants with fever without source (FWS) will be implemented in 7 PEDs, while 4 PEDs will continue with current standard practice and serve as a comparison group.\n\nThe study is expected to run for approximately two years and aims to recruit a minimum of 2,500 febrile infants",[57,58,59,60,61,30,28],"Febrile Illness Acute","Meningitis, Bacterial","Urinary Tract Infection (Diagnosis)","Invasive Bacterial Infection","Serious Bacterial Infection",[63,64,65,66,67,68,69],"Guidelines","Febrile infants","Age ≤60 days","Management","Serious Bacterial Infections","Invansive Bacterial Infections","Clinical prediction tool","2026-04-01",{"date":72,"type":35},"2026-04-02",{"date":74,"type":35},"2025-12-01",{"date":76,"type":22},"2028-09-30",{"name":78,"class":42},"Region Skane",11,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":54,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100630337","evaluation-of-emergency-medicine-pharmacist-impact-on-blood-culture-review-following-emergency-department-discharge-100630337","NCT07486362","Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge","Inclusion Criteria:\n\n* Patients with a positive blood culture result, collected during the initial ED visit and who were discharged from the ED to the outpatient\u002Flong-term care setting prior to a critical blood Groups culture result.\n\nExclusion Criteria:\n\n* Patients admitted to inpatient and patients transferred from ED to another acute care facility.",true,"18 Years",{"count":89,"type":22},126,"6 Months","Patients are commonly discharged from the Emergency Department(ED) with pending blood culture results. Blood cultures can take up to 48 hours to become positive which is why it is important to notify patients with true positive cultures as soon as possible. Delay in notification can lead to other serious complications such as sepsis, septic shock, and death.\n\nThe American College of Emergency Physicians states pharmacists serve a critical role in ensuring efficient, safe, and effective medication use in the ED and advocates for health systems to support dedicated roles for pharmacists within the ED. Pharmacists help to decrease the workload on the healthcare team, especially in the ED where there is high volume and acuity.Emergency medicine pharmacist (EMP) play a significant role in the optimization of therapy, medication safety, and reducing costs.\n\nThere is strong evidence for the positive impact EMPs have on microbiological culture review. Overall, pharmacist review of late cultures results in higher rates of appropriate antimicrobial therapy and decreased missed interventions.These prior studies focused on the review of microbiological tests, including sexually transmitted infections, urine, and wound cultures; however, there was limited data to support the role of pharmacists evaluating late blood culture results.",[30],"2026-03-18",{"date":95,"type":35},"2026-03-20",{"date":97,"type":35},"2024-01-31",{"date":99,"type":22},"2028-01-31",{"name":101,"class":42},"Methodist Health System",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100580538","structural-and-microbiological-characterization-of-arterial-catheter-biofilm-in-icus-patients-using-optical-coherence-tomography-100580538","NCT06838598","Structural and Microbiological Characterization of Arterial Catheter Biofilm in ICU's Patients Using Optical Coherence Tomography","OCT-BIO-KTA","Inclusion Criteria:\n\n* Patient or relative informed of the study and having declared their non-objection\n* Patient over 18 years old\n* Patient hospitalized in ICU with an arterial catheter\n\nExclusion Criteria:\n\n* Patient unable to express consent\n* Patient whose collection of the arterial catheter is impossible or for whom storage at 4°C is impossible\n* Patient with arterial catheter removed outside the usual procedure of the ICU\n* Patient admitted in ICU with an arterial catheter already in place",{"count":111,"type":22},60,"29.3% of bacteremias in intensive care units (ICU) are linked to vascular devices, including 7.7% to arterial catheters, with an influence on both morbility and mortality.\n\nIt is now accepted that biofilm as a role on bacterial development on inner surface of vascular devices but there is yet a lack of clinical relevant data documenting a causal relation between biofilm formation and bacteremias.\n\nThe investigators assume that a better structural and microbiological characterization of arterial catheter biofilm in ICU patients could help preventing bacteremias or have a more specific treatment when it appears.",[114,115,30,116],"Biofilms","Arterial Catheterization, Peripheral","Tomography, Optical Coherence","2026-03-16",{"date":93,"type":35},{"date":120,"type":35},"2024-06-03",{"date":122,"type":22},"2027-12",{"name":124,"class":42},"Centre Hospitalier William Morey - Chalon sur Saône",2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":43},"100611399","phase-4-beta-lactam-plus-levofloxacin-to-enhance-therapy-in-streptococcal-septicemia-100611399","NCT07240077","Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia","Beta-lactam Monotherapy Versus Beta-lactam Plus Levofloxacin for the Treatment of Streptococcal Bacteremia: A Multicenter, Randomized, Double-Blind, Pragmatic Trial","BLESS","Inclusion Criteria:\n\n1. Adults age\\>18 years\n2. Blood culture positive for Streptococcus (\\\u003C72 hours before enrollment)\n\n   * at least 1 bottle of S. pyogenes, S. agalactiae, S. pneumoniae, S. suis\n   * at least 2 bottle of other Streptococci\n3. Receiving or having plan of receiving beta-lactam therapy\n\nExclusion Criteria:\n\n1. Known allergy to beta-lactam or fluroquinolone antibiotics\n2. Pregnancy or lactating mother\n3. EKG with QT prolongation\n4. Diagnosis of infective endocarditis",{"count":135,"type":22},165,[25],"A double-blind randomized controlled trial comparing beta-lactam plus levofloxacin versus beta-lactam monotherapy for the treatment of Streptococcal bacteremia",[30,139],"Streptococcus Infection",[141,142,143],"bacteremia","streptococcus","levofloxacin","NOT_YET_RECRUITING","2025-11-19",{"date":147,"type":35},"2025-11-20",{"date":149,"type":22},"2026-01-01",{"date":151,"type":22},"2028-12-31",{"name":153,"class":42},"Mahidol University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":102},"100551230","echocardiography-versus-no-echocardiography-in-s-aureus-bacteraemia-and-virsta-score--3-100551230","NCT06457386","Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score \u003C 3","Echocardiography Versus no Echocardiography in Individuals With Staphylococcus Aureus Bacteremia and a VIRSTA Score \u003C3: a Non-inferiority Randomized Controlled Trial","VIRSTA-VAL","Inclusion criteria\n\n* Volunteers over 18 years of age;\n* Hospitalized with at least one blood culture positive for Staphylococcus aureus;\n* At the time of inclusion, negative control blood culture performed 48 hours after the first Staphylococcus aureus blood culture collection;\n* VIRSTA score \\\u003C 3; Exclusion criteria\n* Patient with catheter colonization without SAB, defined as positive blood cultures only through vascular access device specimen;\n* Patient referred to the hospital for the management of IE;\n* Contra indication to transthoracic echocardiography (TTE);\n* Echocardiography already performed before inclusion (TTE or TEE) for the current SAB;\n* Pregnancy;\n* Patient under guardianship or trusteeship.\n* Absence of written informed consent from the patient\n* No affiliation to social security (beneficiary or assignee)\n* Subject already involved in another interventional clinical research for which echocardiography must be done\"",{"count":163,"type":22},700,[165],"NA","Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide. Infective endocarditis (IE) has been detected in 5-17% of cases and is a determinant of poor prognosis. The investigators developed a score (the VIRSTA score) based on patients' characteristics to rule out IE with high confidence (negative predictive value (NPV) above 99%) in patients with SAB. This score, with a cut-off of 3 has been externally validated by two international studies which have also established its high NPV. The 2023 European society of cardiology (ESC) guidelines state that echocardiography should be considered in all patients with Staphylococcus aureus bacteremia (SAB) using risk scores (including VIRSTA score) to guide the use or not of echocardiography. While recommended, the investigators think that VIRSTA score must be evaluated in terms of patients' outcome.",[168,30,169],"Staphylococcus Aureus","Infective Endocarditis",[171,172,173,174],"VIRSTA score \u003C 3","Staphylococcus aureus bacteraemia","Echocardiography","Infective endocarditis",{"date":176,"type":35},"2025-11-24",{"date":178,"type":35},"2025-05-14",{"date":180,"type":22},"2028-12",{"name":182,"class":42},"Assistance Publique - Hôpitaux de Paris",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":102},"100607042","impact-of-blood-cultures-drawn-from-arterial-lines-on-the-incidence-of-contamination-detection-of-bacteremia-and-blood-culture-volume-100607042","NCT07183410","Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood Culture Volume","Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood Culture Volume: an Observational Study","Inclusion Criteria:All patients aged 18-99 years who had blood cultures taken as part of their routine care in the intensive care unit for any reason, from January 2024 to January 2027.\n\n\\-\n\nExclusion Criteria:Missing data or patients who did not fullfil the above criteria.\n\n\\-","99 Years",{"count":192,"type":22},1500,"Taking blood cultures is an important and very common procedure in intensive care units due to the high incidence of sepsis and the need for rapid and accurate identification of bacteremia. However, despite the importance of taking a sufficient volume of blood for the purpose of identifying bacterial growth in the blood, the average blood volume in blood cultures at our institution ranges from 3.5-4 ml per bottle (where the desired volume is 10 ml). Taking an insufficient amount of blood reduces the ability of the bacteriological laboratory to detect bacterial growth and thus may lead to a delay or missed diagnosis of bacteremia, identification of the pathogen, and adjustment of appropriate treatment according to sensitivities.\n\nIn intensive care units, most patients are monitored using an arterial catheter, which allows for frequent blood tests without the need to puncture the patient. Following recently published studies that showed that there is no significant difference in the incidence of contamination when taking blood cultures from an arterial catheter compared to a peripheral vein puncture, and in order to improve our ability to identify bacteremia, it was decided to implement a new protocol in the General Intensive Care Unit that includes taking blood cultures from an arterial catheter. According to the new protocol, it was decided that when taking blood cultures from a patient with an arterial catheter, one pair of cultures should be taken from the arterial catheter and another pair from a peripheral vein puncture.\n\nIn this study, we would like to examine the contamination rate of blood cultures, the identification of true bacteremia, and the collection of appropriate blood volume and number of blood specimens taken in patients hospitalized in the General Intensive Care Unit at our institution, while analyzing differences between the period before the implementation of the new protocol and the period after the implementation, and differences between cultures taken from an arterial catheter and from a peripheral vein puncture.",[30],"2025-09-14",{"date":197,"type":35},"2025-09-19",{"date":149,"type":22},{"date":200,"type":22},"2028-06-01",{"name":202,"class":42},"Meir Medical Center",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100494715","reducing-risk-for-infective-endocarditis-100494715","NCT05721781","Reducing Risk for Infective Endocarditis","Reducing Risk for Infective Endocarditis (IE): A Randomized Trial of a Professional Scaling and Oral Hygiene Instruction Intervention to Reduce Tooth Brushing-Associated Bacteremia","PIE-B","Inclusion Criteria:\n\n* Age 18 years or older.\n* Greater than 6 months since last dental hygiene prophylaxis (cleaning).\n* 10 or more accessible teeth (including implants, with a minimum of 8 natural teeth).\n* Willing and able to provide informed consent.\n* Willing to comply with all study procedures and be available for the duration of the study.\n* Willing to forgo routine professional dental cleanings while enrolled in the trial.\n\nExclusion Criteria:\n\n* At high risk for IE, as defined by the 2007\u002F2021 AHA Guidelines:\n* Prosthetic cardiac valve or prosthetic material used for cardiac valve repair.\n* Previous episode of IE.\n* Cardiac transplantation recipient with cardiac valvulopathy.\n* Specific congenital heart disease conditions.\n* Pregnant, by self-report, or planning to become pregnant during the study period.\n* Affected by a condition that, in the opinion of the investigator, may preclude them from study completion or put them at increased risk such as :\n* Hemodialysis dependent.\n* Have a long-term intravascular catheter (e.g., for chemotherapy or parenteral nutrition).\n* Active injection drug use (IDU).\n* Clotting disorder such as, hemophilia.\n* Have a solid organ transplant or hematopoietic stem cell transplant, or ongoing treatment for hematologic cancer.\n* Currently incarcerated.\n* Systemic antibiotic use within the past 2 weeks.\n* Undergoing orthodontic treatment with fixed appliances (brackets and wires) or plans to do so during the study period.\n* Taking or requiring antibiotic prophylaxis prior to dental procedures for other reasons, e.g., to prevent prosthetic joint infection .\n* Three or more teeth with moderate to severe gingival hyperplasia.\n* Has clinically detectable emergent or urgent dental needs that, in the trained and calibrated Oral Examiner's opinion, would require definitive dental care during the study period.",{"count":212,"type":22},320,[165],"This clinical trial is studying if bacteria found in a participant's bloodstream after brushing their teeth can be prevented with a dental cleaning and more education on how to best brush and care for their teeth. One group of participants will have a dental cleaning and oral health instructions and the other group of participants will not. Researchers will compare the blood test results from the two groups to see if the education made a difference in preventing bacteria and how long it stays in the bloodstream.",[30,169],[217,218,219],"Oral Hygiene","Oral Bacteria","Gingival inflammation","2025-08-21",{"date":222,"type":35},"2025-08-22",{"date":224,"type":35},"2023-08-31",{"date":226,"type":22},"2027-09",{"name":228,"class":42},"Wake Forest University Health Sciences",6,{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":237,"targetDuration":239,"studyType":54,"phases":4,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":102},"100602637","prospective-validation-of-grady-a-machine-learning-model-for-early-sepsis-and-bacteremia-detection-in-icu-patients-100602637","NCT07126106","Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients","Prospective Validation of the GRADY Bacteremia\u002FSepsis Prediction Model in Intensive Care Unit Patients: Clinical Performance and Feasibility as an Early Warning System","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* ICU stay of 48 hours or longer\n* Patients from whom blood cultures were obtained during routine monitoring\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* ICU stay shorter than 48 hours\n* Patients without blood cultures",{"count":238,"type":22},55,"12 Months","This study aims to prospectively validate the GRADY prediction models, which use machine learning algorithms to estimate the risk of gram-negative bacteremia and sepsis in intensive care unit (ICU) patients based on routinely collected vital signs and laboratory data. Sepsis, a life-threatening condition associated with high ICU mortality, requires early diagnosis and treatment-yet current diagnostic methods relying on blood cultures are time-consuming. Existing scoring systems such as SOFA, SIRS, and NEWS2 often lack sufficient sensitivity and specificity in early sepsis detection. Unlike traditional tools, the GRADY models seek to provide earlier and more accurate risk stratification. This study will compare the clinical performance of GRADY models against standard scoring systems and explore their integration as early warning tools to support rapid intervention and improve outcomes in critical care.",[30,242],"Sepsis Bacterial",[244,245,246,247],"Bloodstream Infection","sepsis","Machine Prediction Methods","external validation","2025-08-15",{"date":250,"type":35},"2025-08-17",{"date":252,"type":35},"2025-02-01",{"date":149,"type":22},{"name":255,"class":42},"Sisli Hamidiye Etfal Training and Research Hospital",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100337324","phase-4-piperacillin-tazobactam-versus-meropenem-for-treatment-of-bloodstream-infections-caused-by-cephalosporin-resistant-enterobacteriaceae-peterpen-100337324","NCT03671967","PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial","PETERPEN","Inclusion Criteria:\n\n1. Adults (age ≥ 18 years)\n2. New onset BSI due to E. coli or Klebsiella spp. in one or more blood cultures associated with evidence of infection.\n3. The microorganism will have to be non-susceptible to third generation cephalosporins (ceftriaxone and ceftazidime) and susceptible to both PTZ and meropenem (see microbiological methods).\n4. Both community and hospital-acquired bacteremias will be included.\n5. We will permit the inclusion of bacteremias due to E. coli or Klebsiella spp. with concomitant growth in blood of skin commensals considered as contaminants.\n\nExclusion Criteria:\n\n1. More than 72 hr. elapsed since initial blood culture taken, regardless of the time covering antibiotics were started (up to 72 hrs.).\n2. Polymicrobial bacteremia. Polymicrobial bacteremia will be defined as either growth of two or more different species of microorganisms in the same blood culture, or growth of different species in two or more separate blood cultures within the same episode.\n3. Patients with prior bacteremia or infection that have not completed antimicrobial therapy for the previous infectious episode.\n4. Patients with septic shock at the time of enrollment and randomization, defined as at least 2 measurements of systolic blood pressure \\\u003C 90 mmHg and\u002For use of vasopressors (dopamine\\>15μg\u002Fkg\u002Fmin, adrenalin\\>0.1μg\u002Fkg\u002Fmin, noradrenalin\\>0.1μg\u002Fkg\u002Fmin, vasopressin any dose) in the 12 hours prior to randomization. In the absence of the use of vasopressors, a systolic blood pressure \\\u003C90 would need to represent a deviation for the patient's known normal blood pressure.\n5. BSI due to specific infections known at the time of randomization:\n\n   1. Endocarditis \u002F endovascular infections\n   2. Osteomyelitis (not resected)\n   3. Central nervous system infections\n6. Allergy to any of the study drugs confirmed by history taken by the investigator\n7. Previous enrollment in this trial\n8. Concurrent participation in another interventional clinical trial\n9. Imminent death (researcher's assessment of expected death within 48 hrs. of recruitment)",{"count":265,"type":22},1084,[25],"Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.",[269,270,30],"Beta Lactam Resistant Bacterial Infection","Enterobacteriaceae Infections",[141,272,273,274,275],"enterobacteriaceae","extended spectrum beta-lactamase","meropenem","piperacillin tazobactam","2025-07-29",{"date":278,"type":35},"2025-08-01",{"date":280,"type":35},"2019-05-01",{"date":282,"type":22},"2027-04-01",{"name":284,"class":42},"Rambam Health Care Campus",14,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":314,"locationsCount":43},"100599282","epidemiology-of-antimicrobial-use-and-antimicrobial-resistant-infections-in-four-hospitals-in-thailand-100599282","NCT07082465","Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","For primary objectives Inclusion Criteria\n\n* All age and gender\n* Admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024\n* Received a parenteral antibiotic for at least four consecutive days\n* Were still hospitalized on day 8 after starting a parenteral antibiotic\n\nExclusion Criteria\n\n* Admitted as day admissions to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024\n* Had a clinical specimen collected within 2 calendar days of starting a parenteral antibiotic culture positive for an antimicrobial-resistant organism or Staphylococcus aureus\n\nAntimicrobial-resistant (AMR) organism is defined as an organism that is resistant to Access and Low Watch antibiotics, and if the organism is the cause of infection, the recommended antimicrobial therapy involves the use of Medium Watch, High Watch or Reserve antibiotics. The common organisms include methicillin-resistant S. aureus, methicillin-resistant coagulase-negative Staphylococcus spp., ampicillin-resistant Enterococcus spp., vancomycin-resistant Enterococcus spp., 3rd-generation cephalosporin-resistant Gram-negative bacterium and carbapenem-resistant Gram-negative bacterium. The definition of organism includes organisms frequently associated with contamination including coagulase-negative staphylococci, viridans group streptococci, Corynebacterium spp., Bacillus spp., Diptheroid spp., Micrococcus spp. and Propionibacterium spp.. All types of specimens are included (e.g. sputum and tracheal suction). We excluded such patients because the study has no clinical data to differentiate whether the isolated AMR organisms are causing infections or represent colonization.\n\nFor secondary objectives\n\nInclusion Criteria:\n\n* All age and gender\n* Admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024\n\nExclusion Criteria:\n\n• Admitted as day admissions to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024",{"count":293,"type":22},108000,"The main goal of this retrospective observational study is to understand how stepping down antibiotic treatment (called antibiotic de-escalation) affects patients who receive it compared to those who don't after received a short-course (≤7 days) of parenteral antibiotics. The investigators will use past medical records from four public referral hospitals in Thailand from the year 2019 to 2024. The investigators will firstly evaluate which types of patients are more likely to receive antibiotic de-escalation. Then, the investigators will estimate the impact of antibiotic de-escalation, while taking those differences into account. This way, it will help us understand the impact of antibiotic de-escalation in real-world clinical practice. The investigators also aim to assess how accurate automated outbreak detection systems are at detecting outbreaks, evaluate patterns of antimicrobial use and antimicrobial-resistant infections, and develop new indicators for antimicrobial stewardship that are applicable for local and national actions in low and middle-income countries.",[296,297,30],"Drug Resistance","Bacterial",[296,297,30,299,300,301,302,303,304,305,306,307],"Inpatients","Antimicrobial Stewardship","Drug Utilization","Drug Utilization Review","Cluster Analysis","Disease Outbreaks","Epidemiology","Quality Indicators","Health Care","2025-07-15",{"date":310,"type":35},"2025-07-24",{"date":278,"type":22},{"date":313,"type":22},"2026-08-16",{"name":315,"class":42},"University of Oxford",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":102},"100579206","surveillance-of-amr-in-drc-100579206","NCT06821282","Surveillance of AMR in DRC","Surveillance of Antimicrobial Resistance in Semirural Kinshasa, Democratic Republic of Congo: a Feasibility Study","SARKIN","Patients older than six months who present with a clinically suspected bloodstream infection upon admission to the hospital, or who have been hospitalized for less than 48 hours, and provide written consent (or consent from their caregiver\u002Flegal guardian) to participate will be included. Patients with a significant history of healthcare exposure and those with any contraindications for phlebotomy as determined by the clinician's judgment, will be excluded.",{"count":325,"type":22},210,"This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local research capacity. Conducted at a general referral hospital in semirural Kinshasa, DRC, the study will investigate bacterial infections, their resistance profiles, and related risk factors, including co-infections such as malaria.",[30],[329,330,331,332,333],"Antimicrobial resistance (AMR)","Surveillance","Malaria","Africa","Democratic Republic of Congo","2025-02-17",{"date":336,"type":35},"2025-02-20",{"date":338,"type":35},"2024-11-11",{"date":340,"type":22},"2025-09-30",{"name":315,"class":42},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":352,"conditions":353,"keywords":367,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":394},"100284234","fosfomycin-iv-for-treatment-of-severely-infected-patients-100284234","NCT02979951","Fosfomycin I.v. for Treatment of Severely Infected Patients","An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.","FORTRESS","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years\n* Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v.\n* Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC\n* Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)\n\nExclusion Criteria:\n\n* Previous documentation of the patient in the present study\n* Patients participating in an interventional clinical trial\n* Patients with known hypersensitivity to fosfomycin or any of the excipients\n* Terminally ill patients\n* Patients with \"do not resuscitate order\"\n* Palliative treatment approach\n* Failure of \\> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney\n* Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)\n* Fosfomycin treatment as 4th line treatment or at later stage\n* Patients with involvement of fungi or mycobacteria in the targeted infection",{"count":351,"type":22},1000,"The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.",[354,355,356,357,58,358,359,360,361,362,363,364,365,28,30,366],"Bacterial Infections","Bone Diseases, Infectious","Osteomyelitis","Central Nervous System Bacterial Infections","Encephalitis","Brain Abscess","Urinary Tract Infections","Respiratory Tract Infections","Pneumonia, Bacterial","Skin Diseases, Bacterial","Soft Tissue Infections","Intraabdominal Infections","Endocarditis, Bacterial",[368,369,370,371,372,373,374,375,376,377,354,378,379,355,356,357,58,358,359,360,361,362,363,364,365,28,30,366,380,381,382,383],"Observational Study","Non-Interventional Study","Registries","Prospective","Monitored","Multicentric","International","Fosfomycin","Infectofos","Fomicyt","Gram-Negative Bacterial Infections","Gram-Positive Bacterial Infections","Treatment Outcome","Clinical Efficacy","Microbiological Efficacy","Safety","2024-09-27",{"date":386,"type":35},"2024-10-01",{"date":388,"type":4},"2016-12",{"date":390,"type":22},"2030-12",{"name":392,"class":393},"Infectopharm Arzneimittel GmbH","INDUSTRY",50,{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":102},"100548774","impact-of-performing-a-rapid-antibiotic-susceptibility-test-on-antibiotic-therapy-adaptation-in-adult-patients-with-enterobacterales-bacteremia-100548774","NCT06425367","Impact of Performing a Rapid Antibiotic Susceptibility Test on Antibiotic Therapy Adaptation in Adult Patients with Enterobacterales Bacteremia","Impact of Performing a Rapid Antibiotic Susceptibility Test (MHR-SIR) on Antibiotic Therapy Adaptation in Adult Patients with Enterobacterales Bacteremia, Controlled, Randomized Cluster and Cross-over Study","MHR-Blood","Inclusion Criteria:\n\n* age \\>= 18\n* Patient hospitalized in a clinical department of each participating center\n* Patient managed in the context of bacteremia (microbiological criterion = positive blood culture)\n* Patient with positive blood culture for Enterobacterales\n* Patient affiliated to a health insurance scheme\n* Patient\u002Frelative having given free, informed and express oral consent\n\nExclusion Criteria:\n\n* Patients with non-enterobacterial bacteremia\n* Patient under guardianship\n* Patient deprived of liberty\n* Patient under court protection\n* Pregnant or breast-feeding patient",{"count":404,"type":22},960,[165],"Bacteremia is defined as the presence of bacteria in the blood. They can potentially lead to life-threatening septic shock.\n\nEffective probabilistic antibiotic therapy must therefore be initiated immediately after blood cultures have been taken.\n\nTo diagnose bacteremia, blood culture bottles must first be incubated, which allows bacterial growth and early detection. Then, as soon as the sample is positive, an antibiogram of the incriminated bacterium is carried out by inoculation on MH (Mueller Hinton) medium. This diffusion antibiogram is the reference method and is obtained 24 hours after the vial is positive, i.e. around 48 hours after blood cultures are taken.\n\nAmerican recommendations agree that it is crucial to use rapid diagnostic tests to obtain the antibiogram. Antibiotic susceptibility test data can be used to broaden the spectrum of antibiotics in the event of ineffective therapy. They can also be used to reduce the spectrum of broad-spectrum antibiotics. This is part of the proper use of antibiotics and the reduction of multi-resistant bacteria (MRB) or highly resistant bacteria (HRB). Finally, it is also possible to carry out an early oral relay, thus avoiding intravenous infusions and their complications, and potentially reducing hospitalization times.\n\nThe investigators have evaluated a rapid antibiogram by diffusion on MHR-SIR (Mueller-Hinton Rapid-SIR) medium from the blood culture bottle. The investigators were able to obtain antibiogram results 7 hours after blood culture positivity, with excellent correlation compared with the standard method after 24 hours incubation on MH (Mueller-Hinton). The antibiotics tested were the same as with the standard method.\n\nSecondly, The investigators were able to evaluate prospectively the impact of diffusion antibiotic susceptibility testing on MHR-SIR medium on early modification of antibiotic therapy in bacteremia, on 167 patients Antibiotic susceptibility test data on MHR-SIR enabled us to adapt antibiotic therapy 8 hours after blood culture positivity for 74 patients (44%). Antibiotic therapy was ineffective for 30 patients (18%) and was therefore extended. It also enabled us to reduce the spectrum of antibiotic therapy, in particular through early oral relay, for 44 patients (26%).\n\nThe aim of this multicenter trial is to validate on a large scale this strategy for obtaining rapid antibiotic susceptibility test results, with significant consequences in terms of optimizing antibiotic therapy.",[30],[409,141],"antibiogram","2024-09-25",{"date":384,"type":35},{"date":413,"type":35},"2024-08-12",{"date":248,"type":22},{"name":416,"class":42},"Fondation Hôpital Saint-Joseph",{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":102},"100548532","phase-4-an-oral-doxycycline-regimen-to-prevent-bacteremia-following-dental-procedures-100548532","NCT06422221","An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures","Inclusion Criteria:\n\n* Subjects must have at least 10 teeth.\n* Subjects must have the need for a dental extraction under general anesthesia (for behavioral reasons).\n* Subjects will be recruited regardless of the extent and severity of their dental and\u002For periodontal disease.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Body weight under 40 kg\n* Receipt of antibiotics in the previous 3 months\n* Routine use of oral antiseptics\n* A history of allergy or intolerance to doxycycline\n* A history of allergy or intolerance to cindamycin\n* Any type of congenital or acquired immunodeficiency\n* Any known risk factor for bacterial endocarditis\n* Any known risk factor for prolonged bleeding","65 Years",{"count":425,"type":22},150,[25],"Although controversy exists regarding the efficacy of antibiotic prophylaxis for patients at risk of infective endocarditis, expert committees continue to publish recommendations for antibiotic prophylactic regimens. The last American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines include several important changes, highlighting that clindamycin (CLI) is no longer recommended as an alternative to amoxicillin in those allergic to penicillin. This new project aims to evaluate the effectiveness of oral doxycycline in preventing post-dental extraction bloodstream infection.",[30,429],"Endocarditis","2024-06-13",{"date":432,"type":35},"2024-06-17",{"date":434,"type":22},"2024-07-15",{"date":436,"type":22},"2025-06-30",{"name":438,"class":42},"University of Santiago de Compostela",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":464},"100456500","phase-3-pivmecillinam-with-amoxicillinclavulanic-acid-for-step-down-oral-therapy-in-esbl-utis-100456500","NCT05224401","Pivmecillinam With Amoxicillin\u002FClavulanic Acid for Step Down Oral Therapy in ESBL UTIs","Pivmecillinam With Amoxicillin\u002FClavulanic Acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales (PACUTI)","PACUTI","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Fever (≥ 38.3 C) or shaking chills at least once at home or in hospital\n3. Clinical suspicion of UTI including at least one of the following symptoms:\n\n   1. Dysuria, urinary urgency, difficulty urinating, new or worsened urinary incontinence, macroscopic haematuria or increased urinary frequency\n   2. Low abdominal pain or flank pain with percussion or palpation tenderness over kidneys and\u002For bladder.\n4. Urine (≥ 103 CFU\u002FmL) and\u002For blood culture positive for EPE\\* with susceptibility to pivmecillinam†.\n5. In-patient who has received 1-5 days of EPE-active‡ intravenous antibiotics\n6. Discontinuing parenteral treatment and starting treatment with oral antibiotics is considered safe according to the treating physician.\n\n   * EPE refers to ESBL-producing Enterobacterales. This includes Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Klebsiella oxytoca, and Citrobacter koseri.\n\n     * Susceptibility for pivmecillinam in the study is based on zone diameter breakpoints for pyelonephritis (≥ 20 mm) which was received by personal communication with professor Christian Giske, the chairman of the European Committee of Antimicrobial Susceptibility Testing (EUCAST) (26).\n\n       * EPE-active intravenous antibiotics refers to EUCAST susceptibility testing and will most often be piperacillin-tazobactam, meropenem or imipenem-cilastatin in the Swedish setting, and less often aminoglycosides or newer beta-lactamase-inhibitor-containing beta-lactam antibiotics (27). Participants who have only received one dose of EPE-active intravenous antibiotics are also eligible and are considered within the \"1-5 days\" of antibiotics.\n\nPatients may only be recruited and randomised once in this trial.\n\nExclusion criteria (any of the following)\n\n1. Known or suspected pregnancy.\n2. Known or suspected life-threatening allergy towards beta-lactam antibiotics.\n3. Clinical isolate of EPE is resistant to ciprofloxacin, TMX and ertapenem.\n4. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) \\\u003C10mL\u002Fmin or requiring any form of dialysis.\n5. Severe decompensated liver failure (i.e., child Pugh class B or C).\n6. Genetic metabolic diseases associated with severe carnitine deficiency.\n7. Megaloblastic haematopoiesis.\n8. Co-treatment with valproate or valproic acid (due to interaction with pivmecillinam and ertapenem respectively)\n9. Other reason to which patient is unfit to be included in the study according to treating physician, e.g., cognitive impairment preventing informed consent and follow-up, inability to speak and\u002For read Swedish, missing national personal identification number or missing telephone number preventing follow-up or planned duration of antibiotics \\> 10 days due to complicating factors.","130 Years",{"count":449,"type":22},330,[451],"PHASE3","To evaluate if the combination of pivmecillinam and clavulanic acid (PAC) is non-inferior to ciprofloxacin, trimethoprim-sulfamethoxazole or ertapenem as step down oral therapy in patients with febrile UTI caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales (EPE).",[360,30,454],"Antibiotic Resistant Infection","2023-08-25",{"date":457,"type":35},"2023-08-28",{"date":459,"type":35},"2023-05-29",{"date":461,"type":22},"2027-09-01",{"name":463,"class":42},"Lund University",5,{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":17,"minAge":473,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":475,"conditions":476,"keywords":479,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":102},"100125506","lebanese-interhospital-pneumococcal-surveillance-program-100125506","NCT00901602","Lebanese Interhospital Pneumococcal Surveillance Program","Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)","LIPSP","Inclusion Criteria:\n\n* Samples included in the study are those that are:\n\n  * culture proven\n  * invasive pneumococcal infections\n  * in patients of all ages admitted to different hospitals all over Lebanon\n* Acceptable samples include:\n\n  * positive isolates from blood\n  * cerebrospinal fluid\n  * other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration\n\nExclusion Criteria:\n\n* non S. pneumoniae isolates","1 Day",{"count":163,"type":22},"Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.",[477,478,28,30],"Pneumonia","Meningitis",[480,481,482,483,484,141,245],"streptococcus pneumoniae","pneumococcus","pneumonia","meningitis","serotypes","2023-02-02",{"date":487,"type":35},"2023-02-03",{"date":489,"type":4},"2005-10",{"date":491,"type":22},"2030-10",{"name":493,"class":42},"American University of Beirut Medical Center"]